Open Access

Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects

  • Authors:
    • Yu Liu
    • Li Tang
    • Ningning Gao
    • Yuwen Diao
    • Jingjing Zhong
    • Yongqiang Deng
    • Zhulin Wang
    • Guangyi Jin
    • Xiaodong Wang
  • View Affiliations

  • Published online on: June 19, 2020     https://doi.org/10.3892/ol.2020.11762
  • Pages: 2369-2377
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Adjuvant immunotherapy has recently emerged as a potential treatment strategy for breast cancer. The tumor‑associated protein mucin 1 (MUC1) has received increasing attention due to its high expression in numerous types of common tumors, in which MUC1 acts as a cancer antigen. However, the simple mixed composition of an adjuvant and a peptide is not a sufficient rationale for a MUC1 peptide‑based vaccine. The present study developed a novel Toll‑like receptor 7 (TLR7) agonist‑conjugated MUC1 peptide vaccine (T7‑MUC1), which elicited an effective immune response and a robust antitumor effect in a mouse breast cancer model. In vitro, T7‑MUC1 significantly increased the release of cytokines in mouse bone marrow dendritic cells and spleen lymphocytes, and induced the dendritic cell‑cytokine‑induced killer response against tumor cells with high MUC1 expression. In vivo, it was observed that the 4T1 tumor weights in mice immunized with the T7‑MUC1 conjugate were reduced by ≥70% compared with those in the control group. Furthermore, the therapeutic responses in vivo were attributed to the increase in specific humoral and cellular immunity, including high antibody titers, antibody‑dependent cell‑mediated cytotoxicity and cytotoxic T‑lymphocyte activity. The percentages of CD3+/CD8+ T‑cells were significantly higher in the T7‑MUC1 treatment group compared with those in the control group. Therefore, the results of the present study suggested that the T7‑MUC1 vaccine inhibited tumor growth in mice and thus may have potential as a therapeutic candidate in clinical trials for breast cancer immunotherapy.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Tang L, Gao N, Diao Y, Zhong J, Deng Y, Wang Z, Jin G and Wang X: Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects. Oncol Lett 20: 2369-2377, 2020
APA
Liu, Y., Tang, L., Gao, N., Diao, Y., Zhong, J., Deng, Y. ... Wang, X. (2020). Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects. Oncology Letters, 20, 2369-2377. https://doi.org/10.3892/ol.2020.11762
MLA
Liu, Y., Tang, L., Gao, N., Diao, Y., Zhong, J., Deng, Y., Wang, Z., Jin, G., Wang, X."Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects". Oncology Letters 20.3 (2020): 2369-2377.
Chicago
Liu, Y., Tang, L., Gao, N., Diao, Y., Zhong, J., Deng, Y., Wang, Z., Jin, G., Wang, X."Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects". Oncology Letters 20, no. 3 (2020): 2369-2377. https://doi.org/10.3892/ol.2020.11762